Category Asia/Pacific

Fifa Rahman

Will US Drug Pricing Politics Change Intimidation Practices Globally?

Fifa Rahman writes: The global health world, particularly as concerns skyrocketing drug prices and patent abuse, is in a unique space in time. Recently, the Office of the United States Trade Representative (USTR) has been carrying on as per usual. It has threatened the Malaysian and Colombian governments at numerous junctures to prevent them from issuing compulsory licences – a completely legal mechanism which the US uses regularly - to access generic hepatitis C drugs. The Trump Administration has sent delegations to global health agencies in Geneva to intimidate them into reducing, or hiding, work on TRIPS flexibilities and fairer drug pricing.

In Memoriam: Dilip Shah (1941-2019)

Dilip Shah was passionately committed to the twin causes of promoting fair access to medicines around the world, and to the success of the local Indian pharmaceutical industry. A bright light is out, writes Prof. Frederick Abbott.

D G Shah, Founder Of Indian Pharmaceutical Alliance, Dies At Age 77: Economic Times

Dilip Shah, founder of the Indian Pharmaceutical Alliance (IPA) the organisation that represented the interests of Indian drug makers passed away in Mumbai on Friday. He was 77. Known in the industry as "DG", Mr Shah started the IPA when the Indian pharma companies were trying to find their feet in the global pharma landscape that was dominated by the multinational pharma companies predominantly based out of Europe and USA. Shah who himself spent most of his career with the MNC drug companies ...

ASEAN IP Offices Discuss Regional Trademark System

The national intellectual property offices of the 10-member Association of Southeast Asian Nations (ASEAN) this week advanced work on developing a regional trademark registration system, according to European Union sources working with them.

Malaysia Still Under Pressure To Make Hepatitis C Medicine More Expensive

The government of Malaysia continues to face pressure from the United States pharmaceutical industry and potentially the US government to undo an action taken to make a key hepatitis C medicine more affordable in the country. Now Médecins Sans Frontières (MSF, Doctors Without Borders) has weighed in to defend the government's right to use a patent flexibility in global trade law that allows them to take such actions on behalf of their citizens.

Pre-Grant Opposition Filed Against Janssen’s Bedaquiline Fumarate Application In India

Tuberculosis and its variant - Drug Resistant Tuberculosis (DR-TB) - are global public health emergencies. Current treatment regimens are expensive, tedious and prolonged: the overall treatment duration is 20 months or more, requiring daily administration of drugs that are more toxic and less effective than those used to treat drug-susceptible TB. Most of the drugs for treating TB are old and are known to have severe side-effects, writes Sandeep K. Rathod.

US Complaints About Technology Transfer In China: Negotiating The Endgame

Dean Pinkert writes: The United States Trade Representative (USTR) has been open about its view of the difficulties faced by US companies who claim – generally anonymously – that they have been forced to transfer technology to Chinese entities: “The fact that China systematically implements its technology transfer regime in informal and indirect ways makes it ‘just as effective [as written requirements], but almost impossible to prosecute.’” As I explain in this article, I believe such informality is not merely a barrier to prosecutions; it also presents conceptual challenges for US trade negotiators as they attempt to craft effective means to address the concerns of US companies doing business in China.

India Proposes Expediting Patents For Women, Small Entities, Waiving PCT Fees

The Indian Ministry of Commerce and Industry from the Department of Industrial Policy and Promotion recently published draft amendments to the Patent Rules of 2003 that would expand the eligibility for expedited examination of patent applications to include women and small entities, and would waive the fees for online filing of international patent applications through the Patent Cooperation Treaty (PCT), among other changes.